The effect of intralipid on pregnancy rates in in vitro fertilisation (IVF)

Shirlow, Rachael; Healey, Martin; Volovsky, Michelle; MacLachlan, Vivien; Vollenhoven, Beverley

doi:10.1016/j.fertnstert.2016.07.956

Cited by 4 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, they recommended that findings related to ongoing pregnancy and live birth should be investigated further (15). They also defined the use of intralipid as a valuable therapy and advised that its use should be based solely on randomized controlled trial (16). Needless to say, the present study is not without limitations.…”

Section: Discussionmentioning

confidence: 88%

The Effect of Fat Emulsion Intralipid 20% in Reproductive Outcome for Patients With Multiple Implantation Failure

Al-Zebeidi¹,

Lary²,

Al‐Jaroudi³

2017

International Journal of Women’s Health and Reproduction Scienc

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 88%

The Effect of Fat Emulsion Intralipid 20% in Reproductive Outcome for Patients With Multiple Implantation Failure

Al-Zebeidi¹,

Lary²,

Al‐Jaroudi³

2017

International Journal of Women’s Health and Reproduction Scienc

View full text Add to dashboard Cite

“…A large retrospective review of 545 embryo transfers where the patient received intralipid showed no difference in live birth rates compared with control groups. 63 There is a paucity of high-quality studies in this area and side effects of intralipid therapy include pancreatitis, hypercoagulability, and acute respiratory distress syndrome. 64 These alongside the lack of convincing prospective evidence restrict its present use.…”

Section: Intralipid Infusionmentioning

confidence: 99%

Immunological Testing in Assisted Reproductive Technology

Odendaal

Quenby

2021

Semin Reprod Med

View full text Add to dashboard Cite

Fetal implantation requires carefully orchestrated involvement of the maternal immune system. Aberrant function within implantation has been suggested as a cause of implantation failure. The emergence of immunological theories of miscarriage has led to immunological testing as an adjuvant treatment in assisted reproductive technology; however, it remains controversial, with mixed evidence both for immunological cause and the benefits of immunological testing. Literature on common methods of immunological testing within assisted reproductive technology is reviewed including those of peripheral and uterine natural killer cells, chronic endometritis, and T-helper cells cytokine ratio. There is little consensus in the evidence on immunological testing in the context of recurrent implantation failure. The field is limited by a lack of uniformity in approach to testing and heterogeneity of the pathophysiological cause. Nevertheless, the maternal immune system is heavily involved in implantation and the new era of personalized medicine ensures that a more defined approach to immunological testing will be achieved.

show abstract

“…Evidence from both animal 20 and human 3,4,18,21‐23 studies suggests that intralipid administered intravenously may enhance implantation and maintenance of pregnancy. However, not all human studies have shown an improvement in pregnancy outcome after treatment with intralipid 24‐30 . The results of these studies are summarized in Table 1.…”

Section: Success Rates Of Intralipid Therapymentioning

confidence: 99%

“…Chemical pregnancy was recorded for 84 (58.3%) of 144 women in the intralipid group and 76 (50%) of 152 in the control group ( P = .129) 24 . Among the studies that selected patients for treatment based on reproductive history alone, 26‐30 all reported no enhancement after intralipid treatment except one 25 . In one study 21 showing the benefit of treatment with intralipid, 27 of 68 women (40%) with a history of recurrent implantation failure became pregnant after in vitro fertilization and embryo transfer.…”

Section: Success Rates Of Intralipid Therapymentioning

confidence: 99%

Intralipid treatment for women with reproductive failures

Coulam

2020

American J Rep Immunol

View full text Add to dashboard Cite

Does intravenous intralipid treatment for reproductive failure enhance live births? The answer to this question is yes, BUT only in patients that have a diagnosis of recurrent implantation failure (RIF) or recurrent pregnancy loss (RPL) loss AND demonstrate elevated NK (natural killer) cell density in their endometrial biopsy. Live birth rates have been reported between 33% and 42% among women displaying elevated NK activity with a diagnosis of RIF and 75% and 91% among women experiencing RPL after intralipid infusion. When the pregnancy outcomes of women with a history of reproductive failure and elevated NK cells treated with intralipid were evaluated, the overall live birth rate per cycle of treatment was 61%. The results of published studies suggest that intralipid can be used successfully as a therapeutic option to modulate abnormal NK activity in women with reproductive problems.

show abstract

The effect of intralipid on pregnancy rates in in vitro fertilisation (IVF)

Cited by 4 publications

References 2 publications

The Effect of Fat Emulsion Intralipid 20% in Reproductive Outcome for Patients With Multiple Implantation Failure

The Effect of Fat Emulsion Intralipid 20% in Reproductive Outcome for Patients With Multiple Implantation Failure

Immunological Testing in Assisted Reproductive Technology

Intralipid treatment for women with reproductive failures

Contact Info

Product

Resources

About